Last updated: September 7, 2026
IMLYGIC, or talimogene laherparepvec, is Amgen's genetically modified oncolytic herpes simplex virus type 1 therapy for certain patients with unresectable cutaneous, subcutaneous, and nodal lesions from recurrent melanoma. The FDA approved IMLYGIC in October 2015. Its commercial opportunity has remained limited by a narrow label, specialist administration, competition from systemic immunotherapies, hospital-based logistics, and the absence of separately reported product revenue.
Amgen does not disclose IMLYGIC sales as a standalone line item in its public financial filings. The product is included within broader oncology or product categories, preventing a verified annual revenue series. Its biologic exclusivity period is expected to expire in October 2027, although the practical timing of biosimilar or competing biologic entry will depend on development, manufacturing, regulatory, and commercial factors.
What is IMLYGIC and how does it work?
IMLYGIC is an intralesional oncolytic immunotherapy based on a modified HSV-1 virus. It is injected directly into accessible melanoma lesions. The therapy is designed to replicate locally, cause tumor-cell lysis, and stimulate an immune response through expression of granulocyte-macrophage colony-stimulating factor, or GM-CSF.
The FDA indication covers local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery. The label does not position IMLYGIC as a broad first-line replacement for systemic checkpoint inhibitors.
The pivotal OPTiM study compared IMLYGIC with subcutaneous GM-CSF. The trial produced a durable response-rate benefit, but the overall-survival result was more modest and concentrated in selected patient subgroups. These data supported approval but also shaped the drug's commercial positioning as a localized treatment rather than a general melanoma platform therapy (Andtbacka et al., 2015).
What is the FDA regulatory status of IMLYGIC?
| Regulatory milestone |
Date |
| FDA approval |
October 27, 2015 |
| Biologic license application |
Approved under the BLA pathway |
| Therapeutic class |
Oncolytic virus immunotherapy |
| Administration |
Intralesional injection |
| Primary indication |
Unresectable cutaneous, subcutaneous, and nodal lesions in recurrent melanoma |
| Orphan-drug exclusivity |
Approximately seven years from approval |
| Biologic reference-product exclusivity |
Approximately 12 years from approval |
IMLYGIC is regulated as a biologic, not as a conventional small-molecule drug. The FDA's Purple Book is therefore more relevant than the Orange Book for reference-product and biosimilar analysis.
How large is the IMLYGIC market?
The addressable market is materially smaller than the overall melanoma drug market. IMLYGIC requires injectable, accessible lesions and is most useful when disease is localized or regionally concentrated. Patients with widespread visceral metastases, inaccessible lesions, or a need for rapid systemic disease control are more likely to receive systemic immunotherapy.
The principal market constraints are:
- Limited eligibility under the approved label.
- Intralesional administration by trained oncology personnel.
- Cold-chain and viral-product handling requirements.
- Need for repeated dosing.
- Competition from pembrolizumab, nivolumab, relatlimab combinations, and targeted therapies for BRAF-mutated disease.
- Limited evidence for superior survival across the full melanoma population.
- Reimbursement and site-of-care complexity.
The product can have clinical value in patients with injectable lesions, particularly when local tumor control is important or when clinicians seek an immune-priming approach. That value does not translate into a broad market because most advanced melanoma treatment decisions are driven by systemic disease burden, biomarker status, prior therapy, and the need for rapid response.
What are IMLYGIC's sales and financial trajectory?
Amgen has not disclosed IMLYGIC revenue separately in its recent annual reports. The company reports revenue by major product and broader operating categories, but IMLYGIC is not presented as a separately quantified product line. A precise annual sales trajectory therefore cannot be established from public Amgen filings.
| Financial indicator |
Publicly verifiable status |
| Standalone annual revenue |
Not separately disclosed by Amgen |
| Product-level gross margin |
Not disclosed |
| Product-level operating income |
Not disclosed |
| Product-specific guidance |
Not disclosed |
| Revenue concentration |
Small relative to Amgen's major oncology and inflammation products |
| Commercial trajectory |
Mature, niche oncology product with limited public evidence of material growth |
The financial profile is likely characterized by modest revenue relative to Amgen's leading products. IMLYGIC does not have the scale of Repatha, Prolia, XGEVA, Enbrel, or major acquired oncology assets. Its economics are also affected by specialized manufacturing, viral safety controls, storage, distribution, and administration requirements.
Why is IMLYGIC revenue not reported separately?
Amgen's public reporting framework does not provide an IMLYGIC-specific revenue line. The company generally aggregates smaller products into broader categories or reports selected products individually when they meet internal materiality thresholds. Any third-party estimate of annual IMLYGIC sales should therefore be treated as an external market estimate rather than a company-reported figure.
The absence of standalone disclosure has two implications:
- Investors cannot calculate product-level growth, decline, gross margin, or contribution to Amgen earnings from SEC filings.
- Market analysis must rely on prescription data, hospital purchasing data, payer claims, company commentary, and oncology-market research.
How does IMLYGIC compare with competing melanoma drugs?
IMLYGIC competes against therapies that often have broader systemic utility and stronger treatment adoption.
| Therapy |
Company |
Modality |
Principal commercial advantage |
| IMLYGIC |
Amgen |
Intralesional oncolytic virus |
Local lesion treatment and immune stimulation |
| KEYTRUDA |
Merck |
PD-1 inhibitor |
Broad systemic melanoma use |
| OPDIVO |
Bristol Myers Squibb |
PD-1 inhibitor |
Systemic treatment and combination use |
| OPDUALAG |
Bristol Myers Squibb |
LAG-3 plus PD-1 |
First-line advanced melanoma positioning |
| BRAF/MEK combinations |
Multiple companies |
Targeted therapy |
Rapid activity in BRAF V600-mutated disease |
| T-VEC combinations in trials |
Various sponsors |
Oncolytic virus plus checkpoint inhibitor |
Potential immune-priming strategy |
Checkpoint inhibitors have stronger systemic positioning and larger eligible populations. Targeted therapies can produce rapid responses in patients with actionable BRAF mutations. IMLYGIC's differentiation depends on lesion accessibility, local tumor burden, prior therapy, patient condition, and physician willingness to use an intralesional biologic.
What clinical evidence supports IMLYGIC's market position?
The OPTiM trial showed a durable response rate of 16.3% with IMLYGIC versus 2.1% with GM-CSF. The primary endpoint favored IMLYGIC, while the overall-survival analysis did not establish the same magnitude of benefit across the full study population. The strongest clinical rationale has remained local control and potential immune activation rather than broad superiority in metastatic melanoma (Andtbacka et al., 2015).
A major commercial expansion opportunity was the combination of IMLYGIC with pembrolizumab. The phase 3 MASTERKEY-265 study did not meet its primary endpoint for progression-free survival in the first-line advanced melanoma setting. The result reduced the likelihood that IMLYGIC would become a standard backbone for broad checkpoint-inhibitor combinations (Amgen, 2022).
The negative combination result matters financially because a successful combination label could have expanded the addressable population, increased treatment duration, and improved payer and physician adoption. Without that expansion, IMLYGIC remains tied mainly to its original localized-melanoma use case.
When does IMLYGIC lose exclusivity?
IMLYGIC's principal biologic exclusivity is expected to run for 12 years from FDA approval, ending in October 2027. The product also received orphan-drug designation, but the seven-year orphan exclusivity period would have ended approximately in October 2022.
| Protection type |
Approximate end date |
Commercial significance |
| Orphan-drug exclusivity |
October 2022 |
Already expired |
| FDA biologic reference-product exclusivity |
October 2027 |
Key statutory biosimilar barrier |
| Patent protection |
Patent-family specific |
Requires claim-by-claim review |
| Manufacturing know-how |
Potentially ongoing |
May delay practical competition |
The end of biologic exclusivity does not automatically produce a biosimilar launch. A prospective competitor would need to develop a comparable live viral product, establish manufacturing consistency, demonstrate biosimilarity under the Public Health Service Act, and obtain adequate clinical and regulatory support.
What patents protect IMLYGIC?
IMLYGIC protection is likely distributed across several categories:
- Engineered HSV-1 genome and viral construct claims.
- GM-CSF expression and genetic modification claims.
- Viral replication, attenuation, and safety features.
- Cell culture and manufacturing processes.
- Purification, formulation, storage, and handling.
- Methods of treating melanoma with intralesional administration.
- Combination use with immune checkpoint inhibitors.
Patent expiration cannot be reduced to one date without a verified patent-family and terminal-disclaimer analysis. The commercial relevance of any remaining patents will depend on claim scope, validity, written-description support, enablement, prosecution history, and whether a competing product practices the claims.
The principal post-2027 barrier may be manufacturing rather than a single composition patent. IMLYGIC is a replication-competent viral biologic. Product consistency, potency testing, viral identity, contamination controls, stability, and facility qualification create higher development costs than those associated with a conventional injectable generic.
Are there biosimilar or generic entry risks for IMLYGIC?
There is no conventional generic pathway for IMLYGIC because it is a biologic. The relevant competitor would be a biosimilar or potentially a different oncolytic-virus product with a separate BLA.
The near-term entry risk appears limited because:
- IMLYGIC's commercial market is relatively narrow.
- Viral-vector manufacturing is technically demanding.
- The clinical development return may be unattractive without a larger indication.
- A biosimilar would need to compete against established systemic immunotherapies.
- Physicians may prefer a product with extensive postmarketing experience.
- Payers could favor lower-cost alternatives only if clinically interchangeable or contractually advantaged.
A non-biosimilar oncolytic virus could compete through a differentiated indication, delivery method, or combination strategy. Such a product would not necessarily need to copy IMLYGIC's molecular construct, but it would compete for the same oncology budgets and treatment slots.
What patent litigation or settlement agreements affect IMLYGIC?
No major publicly established patent litigation or Paragraph IV settlement involving IMLYGIC is central to its current commercial outlook. Paragraph IV litigation is primarily associated with small-molecule drugs listed in the Orange Book. IMLYGIC is a biologic licensed through a BLA, so the biosimilar litigation framework under the Biologics Price Competition and Innovation Act is more relevant.
Any future dispute would likely concern:
- Biosimilar application patent disclosures.
- Patent dance participation.
- Composition or engineered-virus claims.
- Manufacturing-process patents.
- Interchangeability or labeling issues.
- Trade-secret protection for viral production and quality controls.
The absence of a known major challenge reduces immediate litigation risk but does not eliminate post-exclusivity competition risk.
What licensing deals support the IMLYGIC commercial model?
IMLYGIC originated from BioVex's oncolytic-virus platform. Amgen acquired BioVex in 2011 for approximately $425 million upfront, with potential milestone payments reported at up to approximately $1 billion. The transaction gave Amgen control of the T-VEC program before FDA approval and created the foundation for IMLYGIC's current ownership and development history (Amgen, 2011).
The acquisition economics depended on expanding an early-stage oncolytic-virus platform into a broader oncology franchise. The later failure of the pembrolizumab combination to improve outcomes limited that platform expansion. IMLYGIC remains commercially relevant as an approved product, but the original platform-scale value proposition has not been fully realized.
How strong is the IMLYGIC patent and commercial estate?
The estate is stronger in technical complexity and manufacturing know-how than in market breadth.
| Estate component |
Relative position |
| Approved product status |
Strong |
| Molecular differentiation |
Strong, but potentially design-aroundable |
| Manufacturing complexity |
Strong barrier to rapid entry |
| Broad market coverage |
Limited |
| Combination expansion |
Weakened after negative phase 3 data |
| Orphan exclusivity |
Expired |
| Biologic exclusivity |
Runs to approximately October 2027 |
| Reimbursement leverage |
Moderate to limited |
| Long-term revenue growth potential |
Limited without new indications |
The product's strongest defenses are its approved clinical position, specialized viral manufacturing, regulatory experience, and physician familiarity. Its weaker defenses are the narrow label, competition from systemic immunotherapies, and lack of proven superiority in a broad melanoma population.
What generic launch scenarios exist after 2027?
Scenario 1: No immediate biosimilar entry
This is the most plausible near-term scenario if development economics remain unattractive. Amgen retains the product's established prescriber base, while sales continue at a mature or declining level.
Scenario 2: A delayed biosimilar or follow-on viral product
A competitor could enter after 2027 but face a long development period, limited manufacturing capacity, and uncertain payer uptake. Price erosion would likely be gradual rather than immediate if IMLYGIC remained the only approved product in its precise category.
Scenario 3: New oncolytic-virus competition
A competing virus or intratumoral immunotherapy could reduce IMLYGIC utilization without being biosimilar. The impact would be greatest if the competitor demonstrated better systemic immune effects, easier administration, broader lesion eligibility, or improved combination data.
Scenario 4: Label expansion
A successful new indication or combination could extend the product's commercial life, but the failed MASTERKEY-265 result makes a broad first-line expansion less likely based on current evidence.
What is the geographic coverage of IMLYGIC?
IMLYGIC was developed and commercialized through Amgen's global operations, but its commercial significance is concentrated in markets with:
- Established melanoma treatment centers.
- Intralesional oncology expertise.
- Reimbursement for specialty biologics.
- Regulatory acceptance of oncolytic-virus therapies.
- Infrastructure for viral-product storage and administration.
The United States remains the principal reference market because of the original FDA approval and the size of its oncology-specialty network. European and other-market demand is constrained by health-technology assessment, hospital budgets, administration logistics, and differing reimbursement rules.
What is the investment outlook for IMLYGIC?
IMLYGIC is unlikely to be a major independent driver of Amgen's consolidated financial performance. Its investment relevance is concentrated in three areas:
- Whether Amgen can maintain a profitable niche product through the 2027 biologic-exclusivity date.
- Whether manufacturing complexity limits post-exclusivity competition.
- Whether new data create a viable combination or indication expansion.
The base case is a mature, specialized oncology asset with limited standalone growth and modest post-2027 erosion. A materially better trajectory would require a new clinical setting with larger patient volume and clear comparative value. A worse trajectory would result from declining intralesional use, payer pressure, or replacement by next-generation immunotherapies.
Key Takeaways
- IMLYGIC is Amgen's intralesional talimogene laherparepvec therapy for selected recurrent melanoma lesions.
- FDA approval occurred on October 27, 2015.
- Amgen does not publicly disclose standalone IMLYGIC revenue.
- The product has a narrow market relative to systemic checkpoint inhibitors and targeted melanoma therapies.
- Biologic exclusivity is expected to expire in October 2027.
- Orphan-drug exclusivity expired approximately in October 2022.
- No major public Paragraph IV challenge is central to IMLYGIC because the product is regulated as a biologic rather than a conventional small molecule.
- Viral manufacturing, quality controls, and regulatory complexity may delay biosimilar entry.
- The phase 3 MASTERKEY-265 combination failure reduced the probability of a major market expansion.
- IMLYGIC is better viewed as a mature niche oncology product than as a high-growth Amgen asset.
FAQs
Is IMLYGIC still commercially available?
Yes. IMLYGIC remains an FDA-approved treatment for specified unresectable melanoma lesions. Availability can vary by treatment center, distribution channel, and reimbursement conditions.
Does IMLYGIC have an Orange Book listing?
No conventional Orange Book listing should be expected because IMLYGIC is a biologic licensed under a BLA. The Purple Book and biologic patent-disclosure framework are more relevant.
Can a generic version of IMLYGIC be launched?
No traditional generic can be substituted for IMLYGIC. A competitor would need to pursue a biosimilar or an independent biologic development program.
What caused IMLYGIC's limited market penetration?
The principal factors are its restricted patient population, intralesional delivery, competition from systemic immunotherapies, specialized administration, and limited evidence of broad survival superiority.
Could IMLYGIC revenue increase after 2027?
A post-2027 increase would likely require a successful new indication, combination, or treatment strategy. Loss of biologic exclusivity alone is more likely to create competition risk than revenue growth.
References
Amgen. (2011). Amgen to acquire BioVex, a privately held biotechnology company developing novel oncology and biologic products. Amgen press release.
Amgen. (2022). Amgen provides update on phase 3 MASTERKEY-265 study of IMLYGIC in combination with pembrolizumab. Amgen press release.
Amgen. (2024). 2023 annual report. Amgen Inc.
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., ... Cripps, C. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780-2788.
U.S. Food and Drug Administration. (2015). FDA approves first-of-its-kind product for the treatment of advanced melanoma. FDA press release.
U.S. Food and Drug Administration. (2023). IMLYGIC (talimogene laherparepvec) prescribing information. FDA.
